This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $440,333 to Brigham Young University to characterize a novel Chimeric Autoantigen Receptor (CAAR) treatment for Graves' disease. The goal is to develop a potentially curative immunotherapy that targets the autoreactive B cells responsible for causing Graves' disease, which affects approximately 6.5 million people in the United States. The...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to redefine and improve the management of hypothyroidism. The $172,003 award, effective January 1, 2025 through December 31, 2029, will be used by the University of Chicago to pursue three key objectives: Determine the association between long-term thyroid stimulating hormone (TSH) control and...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
This Cooperative Agreement award under the Trans-NIH Research Support program (CFDA 93.310) was granted by the National Institutes of Health (NIH) Office of the Director to the University of California, Los Angeles (UCLA) for the project "IDENTIFYING NEW IMMUNOTHERAPEUTIC TARGETS FOR ENDOCRINE AUTOIMMUNITY." The $619,346 award, effective September 10, 2024 through June 30, 2029, supports research to delineate the epigenetic and transcriptional mechanisms underlying chronicity in...
The U.S. National Institutes of Health (NIH) awarded a 5-year, $593,823 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Albert Einstein College of Medicine to develop a thrombopoietin (TPO) mimetic peptide (TPOM) as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The key objectives are to: 1) mitigate GI-ARS and determine the dose modification factor of TPOM; 2) elucidate the mechanisms of action of TPOM for radio-mitigation of...
The National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) awarded a $145,636 project grant (CFDA 93.350) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to evaluate the relationship between thyroid hormone levels and brown adipose tissue activity, transcriptome, and cellular composition in adult humans. The study aims to better understand the interaction between the thyroid axis and brown adipose tissue in the process of thermogenesis and energy...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,262,295.00 to Georgia Tech Research Corp to engineer a hydrogel-based human immune organoid to generate activated human B cells and evaluate their in vivo engraftment. The key objectives are to: 1) bioengineer PEG-4MAL-based lymphoid organoids with human B, T, and stromal cells to recapitulate germinal center B cell...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $205,926 to Abbratech Inc., a small disadvantaged biotechnology business located in Branford, CT. The overarching goal of this "Fast Track" research project is to develop a comprehensive platform for identifying and validating recombinant antibodies that target protein isoform splice-junction sites. This addresses key...
This Project Grant award of $1,165,276 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund research to develop a novel biotherapeutic immunocytokine, F5111-IC, to suppress inhibitor formation in hemophilia patients. The primary awardee, Trustees of Indiana University, will investigate the F5111-IC treatment platform to promote immune tolerance and prevent the development of neutralizing antibodies against clotting factor replacement therapy...